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Abstract
ENDOGLIN (ENG) is a co-receptor for transforming growth factor-b (TGF-b) family members that is highly expressed in
endothelial cells and has a critical function in the development of the vascular system. Mutations in Eng are associated with
the vascular disease known as hereditary hemorrhagic telangiectasia type l. Using mouse embryonic stem cells we observed
that angiogenic factors, including vascular endothelial growth factor (VEGF), induce vasculogenesis in embryoid bodies
even when Eng deficient cells or cells depleted of Eng using shRNA are used. However, ENG is required for the stem cell-
derived endothelial cells to organize effectively into tubular structures. Consistent with this finding, fetal metatarsals
isolated from E17.5 Eng heterozygous mouse embryos showed reduced VEGF-induced vascular network formation.
Moreover, shRNA-mediated depletion and pharmacological inhibition of ENG in human umbilical vein cells mitigated VEGF-
induced angiogenesis. In summary, we demonstrate that ENG is required for efficient VEGF-induced angiogenesis.
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Introduction
During development of the embryo, blood vessels evolve de novo
from hemangioblasts that differentiate into endothelial cells and
form a primary vascular plexus. This process is defined as
vasculogenesis [1]. Angiogenesis refers to the remodeling and
maturation of this primitive vascular network into a branched
vascular network [2]. Angiogenesis is a dynamic and carefully
balanced process involving an activation phase associated with
increased vascular permeability, basement membrane degrada-
tion, endothelial proliferation and migration, and a resolution
phase accompanied by inhibition of endothelial cell proliferation
and migration, in parallel with basement membrane reconstitution
[3]. In the maturation phase the recruitment of pericytes and
vascular smooth muscle cells is needed to maintain vessel stability
and protect endothelial cells from apoptosis [4,5].
Vascular endothelial growth factor (VEGF) plays a very
prominent role in vasculogenesis and angiogenesis. VEGF
represents a family of related cytokines, of which the VEGF-A
isoform is a potent endothelial mitogen strongly induced by
hypoxia [6]. Mice lacking one Vegfa allele die at embryonic day
(E)8.5 as a result of vascular malformations [2,7]. VEGF-A
signaling occurs via the high affinity tyrosine kinase receptors
VEGFR1 (FLT-1), and VEGFR2 (FLK-1) [8,9]; VEGFR2 is the
important endothelial VEGF receptor during angiogenesis. Vegfr2
knockout mice die at E8.5 from impaired development of
hematopoietic and endothelial cells [10] and closely resemble
VEGF-A deficient embryos.
Endoglin (ENG or CD105) is a transmembrane glycoprotein
essential for angiogenesis and vascular development, which is
predominantly expressed in vascular endothelial cells [11]. Mice
lacking Eng die at El0.5-E11.5 from angiogenic and cardiovascular
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defects. The early steps of vasculogenesis appear to be normal but
the primary endothelial network fails to remodel into a mature
circulatory system [12–14]. ENG functions as a co-receptor for
transforming growth factor-b (TGF-b) family members, and
interacts with their signaling serine/threonine kinase receptors
[15,16]. TGF-b relays its signal via Type I receptors (TbRI), also
termed as activin receptor-like kinases (ALKs). TbRI acts
downstream of type II receptors (TbRII) [17] and mediates the
activation of intracellular SMAD effector transcription factors
[18]. In endothelial cells, TGF-b can signal via two different
TbRIs, ALK1 and ALK5 [3,19]. Activation of ALK1 induces
SMAD1 or 25 phosphorylation and mediates endothelial cell
proliferation and migration, whereas ALK5 induces SMAD2 and
23 activation leading to vascular quiescence [3,20]. ENG
promotes ALK1/Smad1/5 signaling and inhibits ALK5/
SMAD2/3 signaling [21–23]. ENG and ALK1 have also been
shown to bind other TGF-b family members. Bone morphogenetic
protein (BMP) 9, in particular, can bind directly and with high
affinity to ENG and ALK1 [24,25].
In humans, mutations in Eng lead to hereditary hemorrhagic
telangiectasia type I (HHT1, also known as Rendu-Osler-Weber
syndrome), while HHT2 is associated with mutations in the type I
receptor, ALK1 [26], [27]. HHT is an inherited autosomal-
dominant vascular disorder that affects the blood vessels of many
organs. Characteristic symptoms include epistaxis (nosebleeds),
skin and mucosal telangiectases associated with hemorrhage, as
well as pulmonary, cerebral and hepatic arteriovenous malforma-
tions [28,29].
During the differentiation of mouse embryonic stem cells
(ESCs) in vitro, hematopoietic commitment within Vegfr2+
precursor populations are characterized by Eng expression [30].
In particular, Eng is expressed during the progression from the
Vegfr2+Cd452 to Vegfr22Cd45+ stage, marking the hemangioblast
[31]. In Eng deficient ESCs, the number of hemangioblast
precursors were reduced and myelopoiesis and definitive
erythropoiesis were severely impaired, suggesting that the
regulated expression of ENG functions to support lineage-specific
hematopoietic development from VEGFR2+ expressing precur-
sors [30,31]. Additional studies with forced expression of ENG in
ESCs and transcriptional profiling studies on ENG+ and
VEGFR2+ expressing cells from E7.5 embryos further supported
an important role for ENG in hematopoietic development
[32,33].
In the present study, we examined the role of ENG in
vasculogenesis and angiogenesis using aggregates of ESCs known
as embryoid bodies (EBs). We found that endothelial cell
differentiation was not affected by a lack of ENG, but that
VEGF-induced angiogenesis was severely impaired. The effects
were dependent on the level of Eng: heterozygotes exhibited an
intermediate phenotype, reminiscent of features in HHT1
patients. These results were validated and consolidated by
shRNA-mediated Eng depletion and pharmacological ENG
inhibition studies in endothelial cells. The impaired VEGF-
induced endothelial cell sprouting in the absence of ENG might
provide a suitable cell model to screen for drugs that can rescue
this phenotype, which might lead to novel treatment modalities.
Results
Absence of Eng impairs organization of vascular
structures in 15-day-old embryoid bodies
To elucidate the role of ENG in blood vessel morphogenesis
we examined the effect of Eng gene dosage using the established
assay of differentiation of ESCs into EBs [34]. When induced to
differentiate, Eng+/2 or Eng2/2 ESC lines [13] were found to
form EBs of similar size and compactness to those of wild type
EBs (Fig. 1A). Next, the assembly of vascular structures was
analyzed by platelet endothelial cell adhesion molecule (PE-
CAM)-1 staining of sections of ESC-derived EBs with different
Eng gene dosage (Eng+/+, Eng+/2 or Eng2/2) obtained after
15 days of differentiation embedded in plastic and sectioned
(Fig. lB). Morphology of the vasculature formed in wild type
ESC-derived EBs was very similar to that of the yolk sac in wild
type mouse embryos (Fig. 1B). Multiple blood islands, lined with
a single layer of thin elongated endothelial cells, were found
between the outer endoderm and the inner ectoderm layers
(Fig. 1B), as reported previously by Wang et al. [35]. The number
of blood islands in Eng2/2 ESC-derived EBs appeared less
numerous than in the wild type ESC-derived EBs and
endothelial cells were found in clusters rather than in elongated
single cell layers, confirming the defective formation of vessel-like
structures in Eng2/2 ESC-derived EBs (Fig. 1B). Vascular
structures also developed in Eng+/2 ESC-derived EBs, but their
frequency and organization were markedly reduced compared to
those in wild type ESC-derived EBs, indicating a dose dependent
effect of Eng on vascular organization (Fig. 1B).
ENG does not affect endothelial cell differentiation
Two processes are responsible for the formation of blood vessels
during embryonic development: (i) vasculogenesis, the primary in
situ differentiation of endothelial precursors from mesoderm, and
their organization into a primary capillary plexus and (ii)
angiogenesis, the formation of new vessels by a process of
sprouting from pre-existing vessels [1], [36]. RT-PCR analysis of
endothelial cell specific markers on ESC-derived EBs collected
from days 0 to 20 were used to define the role of ENG during
endothelial cell differentiation. Distinct gene expression patterns
were induced as differentiation proceeded. Vegfr1 was rapidly up-
regulated at day 3 and Vegfr2, Tie-1 and Tie-2 more prominently at
day 5 (Fig. 2A). The expression patterns of the different EC
markers were similar in Eng2/2 ESC-derived EBs. In addition, we
determined the number of PECAM-1 positive cells in dissociated
11-day-old EBs by FACS analysis and found no differences
between wild type, Eng+/2 or Eng2/2 ESC-derived EBs (Fig. 2B).
Analysis of the expression of multiple pericyte-vascular smooth
muscle markers by RT-PCR also did not reveal striking differences
between ESC-derived EBs with different Eng gene dosage (Fig. 2C).
Taken together, our results show that ENG is not required for
endothelial and mural cell differentiation.
Endothelial cell organization is disrupted in Eng2/2
ESC-derived EBs plated on gelatin
EBs plated on a gelatin-coated substrate can develop branching
vascular structures indicative of vascular morphogenesis [37].
Endothelial cells are initially aggregated in dense clusters but when
plated, rapidly form thin branching tubes, in a process resembling
angiogenesis. To determine the role of ENG in this process, we
plated 11-day-old EBs derived from Eng+/+, Eng+/2 and Eng2/2
ESCs and maintained them in culture for four additional days
before staining them with an antibody to PECAM-1 and
hematoxylin to reveal the vascular network. Three different
phenotypes could be identified in the EBs: (i) those with an
extensively branched vascular network without endothelial cell
clusters categorized as ‘‘organized’’, (ii) those forming some vessels
and still containing endothelial cell clusters referred to as
‘‘intermediate’’, (iii) those with endothelial cells clusters only;
these were designated as ‘‘dispersed’’ (Fig. 3A). Of around 90 EBs
scored in each case in two independent experiments, on average
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about 63% of Eng+/+ EBs showed an organized phenotype, ,26%
an intermediate phenotype and only ,11% a dispersed phenotype
(Fig. 3B). By contrast, in the Eng2/2 EBs, ,39% lacked cord-like
structures entirely and were classified as dispersed, whereas ,59%
had an intermediate phenotype. Furthermore, the length of the
vessel sprouts that did form was greatly reduced compared to those
of the Eng+/+ EBs and vessels appeared often wider. Quantitative
analysis also showed that an intermediate vascular phenotype
predominated in the Eng+/2 EBs with,20% dispersed and,60%
intermediate phenotypes (Fig. 3B). When EBs were embedded into
a collagen gel and allowed to form vascular sprouts in 3D, we
Figure 1. Impaired vasculature in Eng null-mutation ESC-derived 11-day-old EBs. (A) Eng+/2 or Eng2/2 ESC lines form EBs with no
difference when compared to EBs derived from wild type ESCs (B) PECAM-1 whole mount immunohistochemistry of representative wild type, Eng+/2,
and Eng2/2 ESC-derived 11-day-old EBs. Wild type ESC-derived EBs form a primitive vascular plexus. In contrast, Eng2/2 ESC-derived EBs form
irregular vascular structures with endothelial cell clusters. Light microscopy of serial plastic sections of wild type, Eng+/2; and Eng2/2 ESC-derived 11-
day-old EBs stained as whole mount for PECAM-1. Black arrowhead indicates vessel like structures. Asterisk indicates endothelial cell clusters.
doi:10.1371/journal.pone.0086273.g001
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observed a reduction in both number of sprouts and sprout length
in the Eng2/2 EBs (Fig. S1).
To validate the data obtained with the Eng2/2 ES cell line we
depleted Eng by shRNAs targeting Eng in ESCs. Essentially we
obtained the same results as for ESCs in which gene dosage was
Figure 2. Expression of endothelial-specific markers during vascular development in EBs. (A) RT-PCR analysis of endothelial cell markers
was performed on ESC and EBs cultured for the indicated number of days. Abbreviations: PECAM, platelet endothelial cell adhesion molecule; tie,
tyrosine kinase with immunoglobulin-like loop and epidermal growth factor homology domain; VEGF, vascular endothelial growth factor receptor (B)
The number of PECAM-1 positive cells was quantified by FACS analysis of the cell suspension of wild type, Eng+/2, and Eng2/2 ESC-derived 11-day-old
EBs. (C) RT-PCR analysis of pericyte-smooth muscle cell markers was performed on ESC and EBs cultured for the indicated number of days. PCR
primers used in this Figure are available upon request. Abbreviations: Aebp, adipocyte enhancer binding protein; Axl, a receptor tyrosine kinase;
Smooth; Smoothelin B; Cspr, cysteine- and glycine-rich protein; Cspg, chondroitin sulfate proteoglycan; Cnn, calpoin; Pdgf, platelet-derived growth
factor, Rgs, regulator of G protein signaling.
doi:10.1371/journal.pone.0086273.g002
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reduced (Fig. 4). Partial knock down of Eng in ESC in
differentiated EBs (Fig. 4B, 4C) interfered with efficient VEGF-
induced sprouting (Fig. 4D), whereas expression of endothelial
markers Vegfr2 and VE-Cadherin mRNA was not significantly
affected (Fig. 4C).
VEGF-induced angiogenesis is reduced in fetal
metatarsals from Eng+/2 mice
In the studies above, VEGF was provided as the angiogenic
stimulus. VEGF is a potent mitogen for endothelial cells and
elevated ENG expression has been associated with activated
endothelial cells in tumor stroma [38]. To investigate a possible
interplay between VEGF and ENG in angiogenesis, we compared
the VEGF-induced angiogenic response in fetal mouse metatarsals
derived from wild type and Eng+/2 mice. After adherence of the
fetal bones to the culture dish, fibroblast-like cells migrate from the
bones to form a monolayer, on which a tubular network of
endothelial cells is formed [38,39]. Staining of this endothelial cell
network with an antibody to PECAM-1 showed that the VEGF-
induced angiogenic responses, as measured by the number and the
length of capillary sprouts were significantly reduced in the Eng+/2
Figure 3. Eng2/2 ESC-derived EBs plated on gelatin coated plates lack organized vessel structures. (A) PECAM-1 immunohistochemical
staining of ESC-derived 11-day-old EBs plated on gelatin for 4 days displayed ‘‘organized’’, ‘‘intermediate’’ or ‘‘dispersed’’ phenotype. (B)
Quantification of wild type, Eng+/2, and Eng2/2 ESC-derived 15-day-old EBs vascular phenotypes as they were defined in A.
doi:10.1371/journal.pone.0086273.g003
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Figure 4. shRNA-mediated knock down of Eng inhibits VEGF-induced endothelial cell sprouting of EBs. ES cells were transduced with
either scrambled or endoglin targeting shRNA. ES cells formed EBs during 4 days of hanging drop culture before embedding in collagen and
stimulation with VEGF (30 ng/ml). Sprouting EBs were analyzed after 8 days of VEGF stimulation. A) Control EBs and EBs with incomplete endoglin
knockdown stained for endothelial marker PECAM-1 (green) and DAPI (blue). Control EBs have large and many outgrowing sprouts of endothelial
cells, which form extensive networks. EBs with incomplete Eng knockdown show less sprouts, which do not seem to form as extensive networks as
control EBs. Sheets of cells that are mostly PECAM-1 negative have formed between the sprouts. B) Control EBs and EBs with incomplete Eng
knockdown stained for ENG (green) and nuclear marker hoechst (blue). ENG is present in the entire sprout in the control EBs, with the highest
expression towards the tip of the sprout. In the EBs with incomplete knockdown showed expression of ENG mainly in the tips of the outgrowing
sprouts. The cellular sheets hardly had ENG expression. C) qPCR analysis of Eng, PECAM-1 and VE-cadherin expression during differentiation of the
ENDOGLIN in VEGF-Induced Angiogenesis
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metatarsals (Fig. 5). This result suggests that ENG is required for
efficient VEGF-induced angiogenesis.
Inhibition of ENG expression or function mitigates VEGF-
induced sprouting of HUVECs
To elucidate the role of ENG in VEGF-induced endothelial
sprouting, we used a 3D-endothelial cell spheroid-sprouting assay,
an established model for studying early in vitro angiogenic
responses [40]. Non-stimulated spheroids of human umbilical
vein endothelial cells (HUVECs) in collagen remain quiescent, and
mimic the quiescent endothelial cells in the vessel wall. When
stimulated with VEGF, tube-like protrusions emerge from the
HUVEC spheroid within one day. We observed that shRNA-
mediated depletion of Eng in HUVECs significantly reduced the
VEGF-induced response in this assay (Fig. 6A, B). In addition,
treatment of HUVECs with the ENG neutralizing antibody
TRC105 also mitigated this response (Fig. 6C), confirming that
inhibition of ENG function attenuates the VEGF-induced
angiogenic response.
Direct VEGF-induced signaling is not affected in Eng-
deficient cells
The data above suggest an involvement of ENG in the VEGF
signaling pathway or crosstalk between ENG and the VEGF
pathway. We therefore further investigated the effect of ENG on
VEGF signaling. The first event in the VEGF signaling cascade is
binding of VEGF to its receptor, VEGFR2. However, specific
depletion of Eng in HUVECs using shRNA did not affect VEGF
binding to VEGFR2 as measured by affinity crosslinking with
radiolabeled VEGF (data not shown). After VEGF-VEGFR2
interaction, VEGFR2 autophosphorylates itself at amino acid
1175, and thereafter initiates activation of the ERK kinase
pathways. However, analysis of VEGF-induced VEGFR2, phos-
pho-ERK pathways did not reveal any significant changes upon
Eng knock down (Fig. 6D). These data indicate that ENG
deficiency does not affect VEGF-induced ERK signaling directly.
Discussion
In the present study, we examined the role of ENG in
vasculogenesis and angiogenesis using aggregates of mouse ESCs
known as EBs that were challenged with angiogenic supporting
factors, including VEGF. Under appropriate conditions, both
vasculogenesis and angiogenesis take place in EBs [41–45]. We
compared EBs from wild type mouse ESCs with those from mouse
ESCs with heterozygous or homozygous deletions in Eng (Eng+/2
and Eng2/2, respectively). We found that the endothelial cell
differentiation program in ESC-derived EBs is not affected by
homozygous deletion of Eng. However, homozygous mutant
endothelial cells were severely inhibited in their ability to form
organized vascular structures either following plating of EBs on
gelatin in 2D or in 3D collagen gels, supporting evidence for an
essential role of ENG in VEGF-mediated angiogenesis. This is
consistent with reports by Bourdeau et al. [13], Li et al. [14] and
Arthur et al. [12], and more recently by Park et al. [46]. However
these data are different from earlier reports on the Eng2/2 ESCs
claiming no effect on endothelial cell organization in differentiat-
ing embryoid bodies. However, different methods were used,
which might have contributed to the different outcomes [47]. To
validate the defect in sprouting of Eng2/2 ESC lines compared
with control Eng+/+ ESC, we depleted Eng by shRNA. Essentially
we were able to confirm the results obtained using the knock out
cells in that they are also defective in VEGF-induced endothelial
cell sprouting, albeit not as dramatically as knock out cells.
shRNA-mediated depletion has the advantage of looking at the
effects of Eng depletion at an early stage, before any long term
adaptation responses occur. Thus, we conclude that ENG is
responsible for the lack of VEGF-induced endothelial vascular
organization.
control and Eng knockdown ES cells. Endoglin expression is reduced by approximately 85% in the ES cells, but during differentiation, at day 7 and 9,
expression is restored to half of the normal levels. Expression of Vegfr2 and VE-cadherin did not significantly differ between control and endoglin
knockdown EBs at the ES cell state or at day 7 and 9 of differentiation. D) Analysis of number of tips per EB. Endoglin knockdown EBs exhibit
significantly less sprouts than the control EBs (p,0.01).
doi:10.1371/journal.pone.0086273.g004
Figure 5. VEGF-induced angiogenesis is impaired in Eng+/2 fetal metatarsal bones.Metatarsals of 17-day-old mouse fetuses were prepared
from wild type and Eng+/2 mice, transferred to cell-culture plates, allowed to adhere, and then stimulated with VEGF (50 ng/ml). (A) Cultures were
fixed and vessel-like structures were visualized by anti-PECAM-1 staining. Six bones were stimulated per experimental group and one representative
picture of each group is shown. (B) VEGF addition stimulated the formation of vessel-like structures. No significant difference in the baseline vascular
network formation was observed between wild type and Eng+/2 metatarsals. The induction of the vascular network of wild type metatarsals is
significantly stronger than the network of Eng+/2 metatarsals. P#0.05.
doi:10.1371/journal.pone.0086273.g005
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We observed interdependence for ENG in VEGF-induced
angiogenic responses. Genetic depletion of Eng from endothelial
cells and pharmacological inhibition using TRC105 ENG
antibody severely affected VEGF-induced endothelial cell sprout-
ing. These results are in line with previous studies, which
demonstrated that ENG is essential for normal growth, migration
and cord formation of endothelial cells [21,48,49]. In addition, our
results are consistent with a recent report that showed that
TRC105 inhibited VEGF and FGF-induced HUVEC endothelial
tube formation when co-cultured with dermal fibroblasts [50].
Moreover, soluble ENG has been shown to inhibit tumor
angiogenesis [51,52], and elevated placental expression of ENG
results in high serum levels of soluble ENG that contribute to
vascular dysfunction in pre-eclampsia [53].
Remarkably, mouse embryonic endothelial cells (MEECs)
isolated from Eng2/2 embryos have been described as exhibiting
Figure 6. Eng deficiency inhibits VEGF-induced sprouting of HUVEC spheroids. (A) Effect of shRNA-mediated depletion of Eng on VEGF-
induced endothelial cell sprouting. HUVECs were transduced with lentivirus expressing endoglin shRNA overnight. HUVEC spheroids with deficient
endoglin expression were embedded in collagen and stimulated with VEGF (50 ng/ml). A representative experiment is shown. (B) Quantitation of
effects seen in (A). (C) Effect of TRC105 ENG antibody on VEGF-induced endothelial cell sprouting. HUVEC spheroids were embedded in collagen and
stimulated with VEGF (50 ng/ml), TRC105 (10 mg/ml), or both overnight. As control antibody for experiments using TRC105, the Fc domain (MOPC-21)
from Bio Express, West Lebanon, NH, was used. Pictures were taken by phase-contrast microscopy. Quantitative analysis of the mean total sprout
length was performed on 10 spheroids per experimental group. P#0.05. (D) VEGF-induced VEGFR2 phosphorylation at site 1175 and extracellular
regulated kinase (ERK) mitogen activated protein (MAP) kinase phosphorylation was examined in shRNA-mediated Eng knockdown cells. Two bands
were detected with the phosphor ERK MAPK antibodies with a molecular weight of 44 and 42 kDa; they represent ERK1 and ERK2 isoforms,
respectively. Number sign (#) represents a background band, indicating the even loading for the experiment. Asterisks indicate the protein bands
with expected size.
doi:10.1371/journal.pone.0086273.g006
ENDOGLIN in VEGF-Induced Angiogenesis
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enhanced proliferation [54]. The basis for the differences between
our findings here and these studies is not clear.One explanationmay
be adaptive mechanisms that take place in endothelial cells in order
to compensate for reduced ENG expression in vivo [21,54–56].
Analysis of yolk sac vasculature in Eng mutant mice has shown
previously that vascular smooth muscle cells are sparse in the
vicinity of vessels lacking endoglin and it was striking that
immunodetectable TGF-bl was reduced in the smooth muscle
cells although TGF-bl mRNA levels in the adjacent endothelial
cells were unaffected [55]. The impaired ability of endothelial cells
to secrete or activate TGF-b1 was believed to explain the lack of
phosphorylated Smad2 in the adjacent mesothelium and the
subsequent failure of these cells to differentiate into vascular
smooth muscle cells. In the EB vasculogenesis assay used here,
vascular smooth muscle cells did form and organize to some
extent, albeit abnormally, in the absence of Eng in contrast to the
observations in vivo. However, the culture conditions used included
the use of fetal bovine serum as a medium supplement, which
could provide active TGF-b and facilitate partial rescue. Since the
EB vasculogenesis assay closely models aspects of vascular
development and includes both the differentiation and organiza-
tional aspects of EC and vascular smooth muscle cell components,
it is potentially useful in screening anti- or pro-angiogenic drugs as
well as in understanding the underlying molecular mechanisms.
In conclusion, our results provide insights into the molecular
mechanisms that underlie vascular defects reminiscent of those in
HHT1 patients and opens new avenues for inhibition of VEGF
signaling by interfering with ENG function.
Materials and Methods
Cell culture
HUVECs. Human umbilical vein endothelial cells (HUVECs)
cells were cultured in Medium 199 with Earle’s salt and L-
glutamine (Gibco), 10% FCS, heparin (LEO pharma), bovine
pituitary extract (Gibco) and penicillin/streptomycin (PS) on plates
coated with 1% gelatin, at 37uC and 5% CO2. HUVECs were
used up to passage 4. Experiments were confirmed with HUVECs
from different donors.
HUVECs were isolated from umbilical cords. The LUMC has
the policy that umbilical cords are considered as ‘‘rest material’’
and collection can be performed without permission of the ethical
committee, provided that the donor of the umbilical cord has
signed a written consent and that collection and processing of the
umbilical cord is performed anonymously. At the LUMC obstetric
unit, where the umbilical cords were collected, the donor of the
umbilical cord was asked to sign a formal waiver. The written
consents are archived at the department of Obstetrics at LUMC
and collection of the umbilical cord was performed anonymously.
Embryonic stem cell lines and culture. Two independent
R1 ESC lines were used as controls. Eng+/2 mouse embryonic
stem cells (ESCs) were generated by gene targeting of the parental
wild-type 129/Ola-derived E14 ES cell lines, deleting 609 base
pairs (bp), including Eng exon 1 and its initiation codon and
leaving the Eng promoter intact [13]. Eng2/2 ESCs were derived in
vitro from Eng+/2 ESCs by selection with high concentrations of
G418 [30]. Genomic DNA was isolated from ESC lines using
standard techniques [57]. Primers MEFI and MERl amplify
normal Exon 1 (300 bp) and primers MEFR1 and MEZR amplify
the recombinant product (476 bp), as previously described [13].
ESC lines were cultured in the presence of mouse embryonic
fibroblasts (MEFs) in DMEM, supplemented with 20% heat-
inactivated fetal bovine serum (FBS), 0.1 mM [3-Mercaptoetha-
nol, lx non-essential amino acids and 1000 U/ml recombinant
Leukemia Inhibitory Factor (LIF).
Lentiviral transduction
HUVECs were infected with lentivirus encoding an shRNA
sequence against human Eng (TRCN0000003273,
TRCN0000003276) selected from the MISSION shRNA library
(Sigma) and a third lentivirus encoding shRNA was generated in
our lab [58]. R1-ES cells were infected with lentivirus encoding an
shRNA targeting mouse Eng (TRCN0000094355, MISSION
shRNA library Sigma). As a control, a non-targeting shRNA
sequence (SHC002) (Sigma) or empty vector pRRL was used.
Virus transduction was performed overnight, and the infected cells
were selected using culture medium containing puromycin (1 mg/
ml) for 48 h. The efficiency of Eng knockdown was verified by
qPCR.
In vitro differentiation of embryonic stem cell clones
Two different methods were used to differentiate ES cells in vitro.
Method 1: ESC lines were cultured in hanging drops to form EBs,
as described previously [59]. Briey, 800 cells were cultured in 20 ml
of DMEM, supplemented with 20% FBS, 25 ng/ml VEGF,
50 ng/ml bFGF-2, hanging from the lid of the culture dish for
5 days, which allows the formation of cell aggregates (EBs). This
makes it possible to control the size of the EBs and circumvents
paracrine stimulation between EBs, and therefore allows a very
high degree of reproducibility. Subsequently, EBs were either (i)
cultured in suspension on bacterial dishes coated with 1% agar for
11 or 15 days. EBs were then washed with PBS and fixed in
methanol (MeOH)-dimethyl sulfoxide (DMSO) in a ratio of 4:1,
overnight (o/n) at 4uC before staining; or (ii) 11-day old EBs were
plated on gelatin coated coverslips for 4 days and then fixed in
Zinc fixative o/n at 4uC before staining.
Method 2: Mixed Feeder-ES cell cultures were trypsinized and
subsequently cultured for 45 minutes on gelatin-coated plates
before the experiment in order to deplete the MEFs, which adhere
faster to the plate. The ES cells were harvested and plated in
suspension as hanging drops of 20 ml in complete ES-medium,
containing 1200 cells/drop, for four days.
Embryoid body maturation in 2D culture
Four-day old EBs obtained with method 2 were plated in
gelatin-coated 6 well-plates with 15–20 EBs per well. EBs were
cultured in ES medium without LIF and supplemented with
50 ng/ml hVEGF-165 (PeproTech, Rocky Hill, USA). After 7 or
9 days, EBs were washed with PBS and RNA was isolated for
qPCR analysis.
Embryoid body maturation in 3-D Collagen matrix
Method 1: All the ingredients of the collagen medium (DMEM,
20% FBS, 25 ng/ml VEGF, 50 ng/ml bFGF-2) with the
exception of collagen were mixed and stored on ice before harvest
of the EBs to avoid prior polymerization of the medium. Prior to
use, rat tail type 1 collagen was added and mixed to a final
concentration of 1.25 mg/ml. 11-day-o1d EBs were immediately
incorporated into the collagen medium at a final concentration of
50 EBs/ml. 12 ml was poured into a 35 mm bacterial grade Petri
dish and cultures incubated for 3 days at 37uC in a 5% CO2
atmosphere [30,42]. For further analysis of sprouting vessels, the
35 mm gel dish was inverted over a 50 mm675 mm glass slide.
The collagen gel was gently laid out on the slide and excess liquid
around the gel removed by pipetting with a dispenser. The gel was
then dehydrated using nylon linen and absorbent filter cards. The
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slide was air-dried for 12 hours and incubated in zinc fixative o/n
at 4uC before staining as previously described [42]. The EBs were
stained for PECAM-1 (Clone MEC13.3, BD Biosciences).
Method 2: Collagen solution was made as following: Purecol
(Advanced Biomatrix, San Diego, USA) with 34.65% HAM’s F12
(Gibco), 6.25% NaOH (0.1M), 6.25% 10x F12, 1.25% 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (1M),
0.975% Sodium bicarbonate 7.5% and 0.625% Glutamax.
Four-day old EBs were suspended in 350 ml collagen and
transferred to a 24-well collagen pre-coated plate (one EB per
well). EBs were cultured in complete ESC-medium without LIF
and supplemented with 30 ng/ml hVEGF-165. The EBs were
cultured for eight days in collagen and the medium was changed
every four days. Afterwards, EBs in collagen were washed with
phosphate buffered saline (PBS) and fixed with 4% paraformal-
dehyde in PBS for 30 min at room temperature.
RNA isolation and quantitative PCR
Total DNA-free cellular RNA was extracted with Trizol
reagents, according to manufacturer’s protocol (Invitrogen).
Samples were DNase I treated to eliminate genomic DNA and
1 mg RNA was reversed transcribed as described [60]. All PCR
analyses of the endothelial cell and SMC specific markers were as
previously described [61]. RNA from ESCs and EBs from method
2 was isolated with the NucleoSpin RNA II kit according to
manufacturer’s protocol (Bioke´, Leiden, Netherlands). qPCR was
performed with SYBRGreen reagent (Roche) for Eng, Vegfr2 and
VE-cadherin. See Table 1 for sequences. The DDCt method was
applied for the expression profiling. Gene expression is normalized
to house-keeping gene GAPDH and wild type ES cells as the
reference sample.
Immunofluorescence staining
For cryosections, ESC-derived l5-day-old EBs were processed as
previously described [62] and subsequently sectioned at 7 mm
before acetone fixation for 10 minutes at 4uC, followed by
30 minutes air drying at RT. Next, slides were permeabilized for
5 minutes with 0.2% Triton X-100 in PBS, followed by blocking
with 2% BSA in PBS at RT for l hour. The slides were then
incubated with rat anti-mouse PECAM-1 (Clone MEC14.7, Santa
Cruz) o/n at 4uC. The slides were then washed four times in PBS
and incubated for 1 hour with goat anti-rat Cy3 (Jackson
ImmunoResearch Laboratories) at RT. The slides were then
washed four times in PBS and mounted in Mowiol before confocal
laser microscope analysis. Slides containing EBs cultured in 3D-
collagen gel and zinc fixed were permeabilized for 15 minutes with
0.2% Triton X-100 in PBS, followed by blocking with TNB
blocking solution for 1 hour at RT, as described above. EBs were
stained with rat anti-mouse PECAM-1 (Clone MEC13.3, BD
Biosciences). The slides were then washed in TBS and incubated
1 hour with donkey anti-rat FITC (Jackson ImmunoResearch
Laboratories) and goat anti-mouse (Jackson IrnmunoResearch
Laboratories) secondary antibodies diluted in TNB. The slides
were then washed four times in TBS and mounted in Mowiol
before confocal laser microscope analysis. EBs matured in 3D
according to method 2 were excised from collagen. The EBs were
blocked in blocking solution (Tris-Buffered Saline Tween (TBST)
with 3% BSA) for 2 hours or overnight at room temperature.
Staining with primary and secondary antibodies was done
overnight. The EBs were stained with Hoechst to visualize the
nuclei. The following antibodies were used: rat anti-mouse
PECAM-1 (BD Pharmingen) and rat anti-mouse ENG (CD105
MJ7/18, BD Pharmingen). Secondary antibodies: donkey anti-rat
Alexa 488 (Invitrogen) and goat anti-rabbit Alexa 594 (Invitrogen).
EBs were stored at 4uC in PBS until analysis with fluorescence
microscopy. Endothelial cell sprouting from the EBs was
quantified by counting the number of sprouts per EB.
Flow Cytometric analysis
To obtain single cell suspensions for FACS analysis, 15-day-old
EBs were collected from agar coated-dishes and washed twice with
PBS before being incubated for 30 minutes in a dissociation
solution containing 0.2% collagenase B (Roche Diagnostics). EBs
were gently ushed every 5 minutes using one ml tip. After
centrifugation, the cell pellet was washed twice with 2% FBS in
PBS and then incubated for one hour at 4uC with a FITC
conjugated anti-mouse PECAM-1 before FACS analysis.
Western blot analysis
HUVECs were seeded in six-well plates and allowed to grow to
90% confluence. Cells were washed with PBS and serum-starved
for 5 hours. Cells were stimulated with VEGF 50 ng/ml for
5 minutes, washed with PBS and lysed in SDS sample buffer.
Samples were boiled for 10 minutes and subjected to SDS-PAGE
and western blotting. Phospho-VEGFRII, phospho-ERK anti-
bodies were purchased from Cell signaling Technology. ENG was
analyzed with an antiserum recognizing human ENG [63].
3D-culture spheroid assay
HUVECs (400 cells per spheroid) were suspended in Medium
M199 containing Earle’s salt and L-glutamine, 10% FBS,
methylcellulose, heparin, bovine pituitary extract, PS and seeded
in non-adherent round-bottom 96-well plates. After 24 hours,
spheroids were embedded into collagen and stimulated with
corresponding stimuli in the presence or absence of inhibitors or
neutralizing antibodies for another 24 hours. As control antibody
for experiments with ENG neutralizing antibody TRC105, the Fc
domain (MOPC-21) from Bio Express, West Lebanon, NH, was
used. EC sprouts were measured by Olympus Analysis software.
Ex vivo fetal mouse metatarsal angiogenic assay
Metatarsals from 17-day-old mouse fetuses from Eng+/+ and
Eng+/2 mice [12] were dissected as described previously [64]. Six
metatarsals per experimental group were transferred to 24-wells
tissue-culture plates containing a-MEM (Gibco), 10% FBS and
penicillin/streptomycin (PS), and allowed to adhere for 4 days.
Then, medium was replaced by fresh medium containing 50 ng/
ml VEGF. Cultures were fixed 7 days after stimulation and vessel
formation was visualized by anti-PECAM-1 staining [39].
Vascular density was quantified by automated image analysis
with Image J. Animal experiments were approved by the
Institutional Committee for Animal Welfare of the Leiden
University Medical Center (LUMC) and were performed accord-
ing to the regulatory quidelines.
Table 1. qPCR primer sequence.
Target Forward primer Reverse primer
Eng GGTCATGACTCTGGCACTCA AGGCGCTACTCAGGACAAGA
Vegfr2 ACCAAGGCGACTATGTTTGC GGGCAAGTCACTTCAATGGT
VE-cadherin ATTGAGACAGACCCCAAACG TGTTTTTGCCTGAAGTGCTG
GAPDH AACTTTGGCATTGTGGAAG ACACATTGGGGGTAGGAACA
doi:10.1371/journal.pone.0086273.t001
ENDOGLIN in VEGF-Induced Angiogenesis
PLOS ONE | www.plosone.org 10 January 2014 | Volume 9 | Issue 1 | e86273
Statistics
All results are expressed as the mean 6 s.d. Statistical
differences were examined by two-tailed Student’s t-test and
P#0.05 was considered to be statistically significant (in the figures,
*P#0.05 and **P#0.01).
Supporting Information
Figure S1 Eng2/2 ESC derived EBs have impaired
endothelial cell-derived vessel structures. A) Bright field
image and PECAM-1 staining of EBs from Eng+/+ and Eng2/2
ESCs. Both bright field image and the PECAM-1 staining show
that the Eng2/2 EB has less endothelial sprouts than the Eng+/+
EB. B) Quantification of the number of sprouts per EB and length
of the sprouts.
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